New blood test may predict bleeding danger for cancer patients on clot drugs

NCT ID NCT06386107

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special blood test, called a thrombin generation assay, can predict bleeding risk in cancer patients who are taking blood thinners for blood clots. Researchers will follow 212 patients for 6 months, measuring their blood's clotting ability and tracking any bleeding events. The goal is to see if this test can help doctors choose safer treatments for cancer-associated thrombosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Thrombin Generation Assay (blood test)
What this could lead to: If successful, this could lead to a blood test that helps doctors predict bleeding risk in cancer patients on anticoagulants, allowing safer treatment choices.
What could go wrong: This is an observational study, not a treatment trial. The test may not reliably predict bleeding, and results may not change clinical practice without further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm pulmonary embolism thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER PULMONARY EMBOLISM THROMBOSIS

Contacts and locations

Locations

CHU de Grenoble
NOT_YET_RECRUITING

Grenoble, 38043, France
Chu Clermont-Ferrand
NOT_YET_RECRUITING

Clermont-Ferrand, 63003, France
Chu St-Etienne
RECRUITING

Saint-Etienne, 42055, France
HCL
NOT_YET_RECRUITING

Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.